No Data
No Data
Henan Lingrui Pharmaceutical (600285): The profit growth in 2024 is remarkable. The "R&D + mergers and acquisitions" strategy enriches the product matrix.
Profit growth is impressive, maintaining a "Buy" rating. The company achieved a revenue of 3.5 billion yuan in 2024 (year-on-year +5.72%, all following figures are year-on-year); net income attributable to the parent company is 0.723 billion yuan (+27.19%); excluding non-recurring items.
Henan Lingrui Pharmaceutical (600285): Performance meets expectations. Bullish on Silver Valley's new momentum.
Investment Highlights: Henan Lingrui Pharmaceutical released the 2024 annual report and the first quarter report of 2025, achieving revenue of 3.501 billion yuan in 2024 (up 5.72% year-on-year), with net income attributable to shareholders of 0.723 billion yuan (up 27%).
Ling Rui Pharmaceutical 2024 Annual Report
Summary of Lingrui Pharmaceutical\'s 2024 Annual Report
Lingrui Pharmaceutical\'s 2025 First Quarter Report
Henan Lingrui Pharmaceutical (600285.SH) released its first-quarter results, with a net income of 0.217 billion yuan, a year-on-year increase of 13.89%.
Henan Lingrui Pharmaceutical (600285.SH) released its first quarter report for 2025, with the company's first quarter revenue of 10...